T. Rowe Price Associates
DRNA

T. Rowe Price Associates’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

T. Rowe Price Associates’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,682,596
Closed -$54.1M – 3082
2021
Q3 		$54.1M Buy
2,682,596
+699,671
+35% +$19.3M 0.01% 976
2021
Q2 		$74M Buy
1,982,925
+289,743
+17% +$8.88M 0.01% 891
2021
Q1 		$43.3M Sell
1,693,182
-379,035
-18% -$9.68M ﹤0.01% 1052
2020
Q4 		$45.7M Sell
2,072,217
-21,461
-1% -$473K ﹤0.01% 991
2020
Q3 		$37.7M Sell
2,093,678
-300,804
-13% -$6.23M ﹤0.01% 968
2020
Q2 		$60.8M Sell
2,394,482
-232,744
-9% -$5.01M 0.01% 785
2020
Q1 		$48.3M Sell
2,627,226
-653,798
-20% -$12.7M 0.01% 799
2019
Q4 		$72.3M Buy
3,281,024
+2,004,112
+157% +$40.3M 0.01% 777
2019
Q3 		$18.3M Buy
1,276,912
+123,913
+11% +$1.77M ﹤0.01% 1181
2019
Q2 		$18.2M Buy
1,152,999
+406,960
+55% +$5.53M ﹤0.01% 1202
2019
Q1 		$10.9M Buy
746,039
+413,424
+124% +$4.75M ﹤0.01% 1308
2018
Q4 		$3.56M Buy
+332,615
New +$4.37M ﹤0.01% 1444
2018
Q2 		– Sell
-83,594
Closed -$799K – 2613
2018
Q1 		$799K Buy
+83,594
New +$901K ﹤0.01% 1881
2014
Q2 		– Sell
-172,800
Closed -$4.88M – 2555
2014
Q1 		$4.88M Buy
+172,800
New +$6.42M ﹤0.01% 1436

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.76B AUM 40.74% 1-Year Est. Return

T. Rowe Price Associates's DRNA Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 2,682,596 shares — an estimated $54.1M sold.

T. Rowe Price Associates first reported a position in DRNA in Q1 2014 and held it in 14 quarters. The position peaked at $74M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,682,596 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $54.1M.
  • T. Rowe Price Associates first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 14 quarters.
  • T. Rowe Price Associates's Dicerna Pharmaceuticals, Inc. position peaked at $74M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.